GenomeWeb

GenomeWeb is a standalone online news platform located in New York. Since its inception in 1997, GenomeWeb has been dedicated to providing valuable information to the worldwide community of scientists, tech experts, and leaders involved in the innovative tools used in molecular biology research and diagnostics.

National, Trade/B2B

English

Blog

Outlet metrics

Domain Authority

Ranking

Global

#353965

United States

#148551

Health/Health Conditions and Concerns

#350

Traffic sources

Monthly visitors

Articles

New Data at ASCO Showcase Efforts to Use Liquid Biopsy to Guide Adaptive Cancer Therapy

1 day ago | genomeweb.com | Molika Ashford

NEW YORK – New research presented this week at the annual meeting of the American Society for Clinical Oncology showcased some early efforts to use liquid biopsy testing to adapt cancer treatment in real time, in this case in patients with head and neck tumors.
MCED Developers Share New Data at ASCO as Stakeholders Weigh Harms and Benefits

2 days ago | genomeweb.com | Molika Ashford

NEW YORK – This year's annual meeting of the American Society of Clinical Oncology featured new data from a slew of test developers advancing multi-cancer early detection (MCED) technologies, alongside tactful discussion including oncologists and patient advocates acknowledging continued uncertainty about the true utility of these assays.
ASCO Data on Personalis Assay Suggests Role for ctDNA MRD Testing in Cervical Cancer

3 days ago | genomeweb.com | Molika Ashford

NEW YORK – New data presented this week at the annual meeting of the American Society of Clinical Oncology in Chicago has set the stage for the potential future use of molecular residual disease testing to prognosticate and personalize treatment of cervical cancer.
Evidence for ctDNA as Breast Cancer Progression Marker Builds But More Data Still Needed

4 days ago | genomeweb.com | Forest Ray

NEW YORK – Data from several clinical trials presented at the American Society of Clinical Oncology's annual meeting this week support the use of circulating tumor DNA (ctDNA) to guide therapy decisions before clinical progression in early and metastatic breast cancer.
Clinical Validation Data for Freenome Blood-Based CRC Test Shows 'Acceptable' Screening Accuracy

4 days ago | genomeweb.com | Andrea Anderson

NEW YORK – A team led by investigators at Kaiser Permanente and cancer test developer Freenome has demonstrated that a blood-based assay for circulating tumor DNA can be used to detect colorectal cancer (CRC) with "acceptable accuracy" in a screening setting involving an average-risk population. The findings appeared in the Journal of the American Medical Association on Monday.
Razor Genomics Assay Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer Patients

6 days ago | genomeweb.com | Kelsy Ketchum

CHICAGO – In an abstract presented at the American Society of Clinical Oncology's annual meeting on Saturday, researchers demonstrated that Razor Genomics' RiskReveal 14-gene assay could help clinicians determine which patients with early-stage non-squamous non-small cell lung cancer should undergo adjuvant chemotherapy after surgery.
Geneseeq Prepares for Broader Commercialization of Fragmentomic MCED, Single-Cancer Tests

1 week ago | genomeweb.com | Forest Ray

NEW YORK – Geneseeq sees a path to broader commercialization of its CanScan liquid biopsy multicancer early detection (MCED) test, following encouraging interim data from an ongoing multiphase study taking place in China that was published this week in Nature. The multiphase study aims to determine the feasibility of MCED testing using Geneseeq's CanScan assay in an outpatient setting, targeting asymptomatic adults between the ages of 45 and 75.
Predicta Biosciences Begins Commercialization of Blood Cancer Tests

1 week ago | genomeweb.com | Kelsy Ketchum

NEW YORK – Precision oncology firm Predicta Biosciences last month took the first step in the product commercialization process by launching its whole-genome sequencing-based GenoPredicta assay for multiple myeloma.
Swiss Startup Parithera Launches With Plans to Bring CTC Sequencing Platform to Clinical Market

1 week ago | genomeweb.com | Andrew P. Han

NEW YORK – Parithera, a single-cell sequencing technology company, has emerged from stealth with plans to bring circulating tumor cell (CTC) analysis to the clinical market. The Switzerland-based startup is planning to sell an instrument and kit that isolates rare cells, especially CTCs, for genomic analysis.
ESHG: Studies Demonstrate Potential of Long-Read Sequencing in Rare Disease Diagnostics

1 week ago | genomeweb.com | Julia Karow

NEW YORK – Manufacturers of long-read sequencing platforms have long touted the technology's potential in rare disease diagnostics because it can detect structural variants, short tandem repeats (STRs), and methylation signatures in a single assay. However, cost, informatics requirements, and other implementation hurdles have hindered its wide adoption so far.